These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
15. Translational public health care perspective: intravitreal treatment of neovascular age-related macular degeneration has revolutionized clinical ophthalmology. Bloch SB; Larsen M Acta Ophthalmol; 2015 Mar; 93(2):103-4. PubMed ID: 25688486 [No Abstract] [Full Text] [Related]
16. Retinal venular calibre dilatation after intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Wickremasinghe SS; Guymer RH; Wong TY; Kawasaki R; Wong W; Qureshi S Clin Exp Ophthalmol; 2012; 40(1):59-66. PubMed ID: 21668787 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. Mekjavic PJ; Kraut A; Urbancic M; Lenassi E; Hawlina M Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774 [TBL] [Abstract][Full Text] [Related]
18. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes. Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082 [TBL] [Abstract][Full Text] [Related]
19. Is This a 737 Max Moment for Brolucizumab? Rosenfeld PJ; Browning DJ Am J Ophthalmol; 2020 Aug; 216():A7-A8. PubMed ID: 32505363 [No Abstract] [Full Text] [Related]
20. Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration. Hosseini H; Lotfi M; Esfahani MH; Nassiri N; Khalili MR; Razeghinejad MR; Nouri-Mahdavi K Retina; 2012 May; 32(5):967-71. PubMed ID: 22146127 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]